MX368767B - (5,6-dihidro)pirimido[4,5-e]indolizinas. - Google Patents

(5,6-dihidro)pirimido[4,5-e]indolizinas.

Info

Publication number
MX368767B
MX368767B MX2016012997A MX2016012997A MX368767B MX 368767 B MX368767 B MX 368767B MX 2016012997 A MX2016012997 A MX 2016012997A MX 2016012997 A MX2016012997 A MX 2016012997A MX 368767 B MX368767 B MX 368767B
Authority
MX
Mexico
Prior art keywords
indolizines
pyrimido
dihydro
cancer
aryl
Prior art date
Application number
MX2016012997A
Other languages
English (en)
Other versions
MX2016012997A (es
Inventor
Petrus Antonius De Man Adrianus
Christian Buijsman Rogier
Gerard STERRENBURG Jan
Cornelis Marinus UITDEHAAG Joost
Johannes Petrus DE WIT Joeri
Jenny Rudolf Zaman Guido
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Publication of MX2016012997A publication Critical patent/MX2016012997A/es
Publication of MX368767B publication Critical patent/MX368767B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un compuesto de fórmula I: (ver Fórmula) Fórmula I, en donde, R1 y R2 se seleccionan independientemente entre el grupo que consiste de arilo de (C6-10) opcionalmente sustituido y grupos heteroarilo de (C1-5); los compuestos se pueden utilizar en composiciones farmacéuticas, en particular en el tratamiento del cáncer.
MX2016012997A 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinas. MX368767B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (2)

Publication Number Publication Date
MX2016012997A MX2016012997A (es) 2016-12-07
MX368767B true MX368767B (es) 2019-10-15

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012997A MX368767B (es) 2014-04-07 2015-03-30 (5,6-dihidro)pirimido[4,5-e]indolizinas.

Country Status (16)

Country Link
US (2) US9856258B2 (es)
EP (1) EP3129374B1 (es)
JP (1) JP6518690B2 (es)
KR (1) KR102432420B1 (es)
CN (1) CN106132963B (es)
AU (1) AU2015243694B2 (es)
BR (1) BR112016022342B1 (es)
CA (1) CA2944610C (es)
DK (1) DK3129374T3 (es)
ES (1) ES2716165T3 (es)
HU (1) HUE043108T2 (es)
MX (1) MX368767B (es)
PL (1) PL3129374T3 (es)
PT (1) PT3129374T (es)
RU (1) RU2692479C2 (es)
WO (1) WO2015155042A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180011089A (ko) * 2015-04-17 2018-01-31 네덜런즈 트랜슬레이셔널 리서치 센터 비.브이. Ttk 억제제 화학요법을 위한 예후 바이오마커
CA3014395A1 (en) * 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
SG10202110874TA (en) 2016-06-07 2021-11-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
JP6878615B2 (ja) 2017-03-23 2021-05-26 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
AU2022414970A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases
AU2022415783A1 (en) * 2021-12-15 2024-06-27 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
RS20050944A (en) 2003-05-22 2008-06-05 Nerviano Medical Sciences S.R.L., Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2008065054A1 (en) 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
JP5542133B2 (ja) * 2008-06-26 2014-07-09 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピラゾロ−キナゾリン
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
EP2424868B1 (en) 2009-04-29 2018-01-10 Nerviano Medical Sciences S.r.l. Cdk inhibitor salts
US8648078B2 (en) 2009-07-29 2014-02-11 Nerviano Medical Sciences S.R.L. PLK inhibitor salts
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
EP2668190B1 (en) * 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
EP3013823B1 (en) 2013-06-24 2017-11-01 Merck Patent GmbH Imidazole compounds as modulators of fshr and uses thereof

Also Published As

Publication number Publication date
USRE48974E1 (en) 2022-03-15
AU2015243694B2 (en) 2019-01-17
CA2944610C (en) 2024-01-09
RU2016141405A (ru) 2018-05-07
ES2716165T3 (es) 2019-06-10
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
RU2016141405A3 (es) 2018-10-02
JP2017510595A (ja) 2017-04-13
HUE043108T2 (hu) 2019-07-29
CA2944610A1 (en) 2015-10-15
BR112016022342A8 (pt) 2021-07-20
CN106132963A (zh) 2016-11-16
CN106132963B (zh) 2019-08-06
MX2016012997A (es) 2016-12-07
AU2015243694A1 (en) 2016-11-03
BR112016022342A2 (pt) 2017-08-15
BR112016022342B1 (pt) 2022-10-04
PL3129374T3 (pl) 2019-07-31
JP6518690B2 (ja) 2019-05-22
EP3129374B1 (en) 2018-12-19
KR102432420B1 (ko) 2022-08-17
KR20170013866A (ko) 2017-02-07
PT3129374T (pt) 2019-03-25
US9856258B2 (en) 2018-01-02
DK3129374T3 (en) 2019-04-08
RU2692479C2 (ru) 2019-06-25
EP3129374A1 (en) 2017-02-15

Similar Documents

Publication Publication Date Title
MX2016012997A (es) (5,6-dihidro)pirimido[4,5-e]indolizinas.
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
CA2999253C (en) Heterocyclic compounds and uses thereof
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018015094A (es) Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos.
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
MY190243A (en) Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
JO3195B1 (ar) مشتقات أندوليزين جديدة, وطريقة تحضيرهم والتركيبات الصيدلانية التي تحتوي عليهم لعلاج السرطان
EP3597649B8 (en) Compositions containing substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
MD4820C1 (ro) Compuşi dihidroizochinolinonici substituiţi
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
JO3310B1 (ar) مشتقات إندوليزين جديدة وطريقة لإنتاجها وتركيبات صيدلانية تحتوي عليها
TN2015000262A1 (en) Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors
AU2015352440B2 (en) Compounds
TW201613864A (en) Novel compounds
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EP3250572A4 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
PH12017500342A1 (en) 7 - (morpholinyl) -2- (n-piperazinyl) methyl thieno [2,3-c] pyridine derivatives as anticancer drugs
PH12016501997A1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2017006051A (es) Derivados de 2,3-dihidro-tiazolo[3,2-a]piridin-5-ona, intermediarios de los mismos, y su uso como agentes antibacterianos.

Legal Events

Date Code Title Description
FG Grant or registration